Carl Zeiss Meditec AG Implements Strategic Measures Amid Earnings Decline

Carl Zeiss Meditec AG announced a 5.7% revenue decline to €991.0 million in the first half of fiscal 2025/26 compared to the previous year. Adjusted EBITA fell significantly to €60.5 million from €112.6 million, driven by adverse currency effects and challenges in the intraocular lens market. Additionally, the Americas faced a weak capital spending environment due to geopolitical uncertainties.

To address the downturn, Carl Zeiss Meditec unveiled a robust package of measures aimed at restoring profitability and supporting long-term growth. The company plans to achieve over €200 million in annual earnings improvement by fiscal 2028/29 through procurement optimization, portfolio adjustments, and cost reductions, including potential job cuts of up to 1,000 positions.

The company expects these initiatives, alongside infrastructure investments, to promote a sustainable EBITA margin recovery. Revenue projections for fiscal 2025/26 are set at €2.15–2.20 billion, with an anticipated EBITA margin of 8% to 10%.